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We performed a prospective study to examine the genetic eﬀect on the response to a calcium (Ca) channel blocker, azelnidipine
and an ACE inhibitor, temocapril treatment in patients with hypertension, as a part of the prior clinical trial, the Azelnidipine and
Temocapril in Hypertensive Patients with Type 2 Diabetes Study (ATTEST). Methods and Results. All subjects who gave informed
consent for genetic research were divided into two groups: the subjects treated with azelnidipine or temocapril, for 52 weeks. We
selected 18 susceptible genes for hypertension and determined their genotypes using TaqMan PCR method. RNA samples were
extracted from peripheral blood, and quantitative real time PCR for all genes was performed using TaqMan method. One of the
polymorphismsoftheRGS2genewasextractedasbeingabletoinﬂuencetheeﬀectofthesetreatmentstoreduceBP.Ateightweeks,
BP change showed a signiﬁcant interaction between the A-638G polymorphism of Regulator of G protein signaling-2 (RGS2) gene
and treatment with azelnidipine or temocapril. There was no gene whose expression was associated with BP phenotypes or the
polymorphisms of each gene. Conclusions. A-638G polymorphism of the RGS-2 gene could be a predictive factor for therapeutic
performance of Ca channel blockers.
1.Introduction
Genetic approaches may provide a powerful tool for clarify-
ing the pathogenesis of essential hypertension. Many reports
have demonstrated that gene polymorphisms of the renin-
angiotensin system (RAS) are associated with hypertension.
T h e r eh a v eb e e ns o m er e l i a b l er e p o r t sa b o u ts u s c e p t i b l e
genes for hypertension including the results from “The
Millennium Genome Project for Hypertension in Japan
(2000∼2005) [1, 2]; however, no convincing gene has yet
been detected. Some of the genes regulating blood pressure
might also be related to the response to antihypertensive
medication [3, 4]. Indeed, we and other collaborators have
investigated several susceptible genes related to hypertension
[5–15], including genes of not only the renin-angiotensin
system and sodium handling but also insulin resistance,
oxidative stress, and sympathetic nervous system (described
in the Section 2); however, the genes involved in the
response to antihypertensive medication have not yet been
identiﬁed. In addition, exhaustive gene expression analysis
(transcriptome analysis) for lifestyle-related diseases has not
been performed thus far. We performed a large collaboration
with the study group led by Professor Katayama at Saitama
Medical University to perform a randomized controlled trial2 International Journal of Hypertension
called “Azelnidipine (a calcium (Ca) channel blocker) and
Temocapril (an ACE inhibitor) in Hypertensive Patients with
Type 2 Diabetes Study (ATTEST) [16]”, which included
genetic analysis to evaluate the therapeutic eﬀects of azelni-
dipine and temocapril.
The goals of this study were, ﬁrst, to assess the asso-
ciation between polymorphisms of susceptible genes for
hypertension (18 genes) and each treatment or phenotype
and, second, to assess the association between expression in
peripheral blood of susceptible genes for hypertension and
each treatment or phenotype.
2. Methods
2.1. Study Subjects. ATTEST Study, a multicenter, ran-
domized, open-label study, was originally performed to
investigate the eﬃcacy and safety of combination therapy
using the calcium channel blocker (CCB) azelnidipine and
angiotensin-converting enzyme (ACE) inhibitor temocapril
in hypertensive diabetics, led by Professor Katayama of
Saitama Medical University. All of the subjects fulﬁlled the
following inclusion criteria: (1) age: 30∼70 years, outpa-
tients, (2) mean systolic BP (BP): 140∼180mmHg and/or
mean diastolic BP: 90∼110mmHg in washout period (four
weeks) and stable BP without ﬂuctuation in systolic BP of
more than 30mmHg or diastolic BP of more than 15mmHg,
and (3) fasting blood glucose: more than 126mg/dl or
HbA1c: more than 6.5% at 6 months before entry. These
mild or moderate hypertensive subjects with diabetes were
treated with the following medication: CCB: azelnidipine
and ACE inhibitor: temocapril in accordance with the
protocol (Figure 1). Each medication was started at a dose
of 8mg azelnidipine or 2mg temocapril and increased to
16mg azelnidipine or 4mg temocapril until BP of less than
130/80mmHg was achieved. All subjects were measured for
body height, body weight, systolic BP, diastolic BP, fasting
blood glucose level, triglyceride level, low density lipoprotein
(LDL) cholesterol level, and serum creatinine (Cr) level.
Informed consent for genetic analysis was obtained from
all subjects, and ﬁnally a total of 44 subjects were recruited in
this study.
2.2. Selection of Susceptible Genes for Hypertension and
Genotyping and Quantitative Real Time PCR (RT-PCR).
The 18 genes shown in Table 1 were selected for the
current study. All of the genes were previously reported
to be susceptible genes for hypertension. The genotypes of
the 22 polymorphisms of the 18 susceptible genes (ACE
Ins/del, ADD1 Gly460Trp (rs4961), ADIPOQ Ile164Thr,
ADRB1 Ser49Gly (rs1801252) and Arg389Gly (rs1801253),
ADRB2 Gly16Arg (rs1042713) and Glu27Gln (rs1042714),
ADRB3 Trp64Arg (rs4994), AGT Met235Trp (rs699),
AGTR1 A1166C (rs17231380), ALDH2 Glu487Lys (rs671),
ARHGAP8 Arg338Gly (rs6007334), BDKRB2 T-58C, FASL
G-670A, GRK4 Ala486Val (rs1801058) and Arg65Leu
(rs2960306), hOGG1 Ser326Cys (rs1052133), MTHFR
C677T (rs1801133), RGS2 A to G in promoter (rs3767489),
RGS2 A-638G (rs2746071), SLC12A3 Arg904Gln
Table 1: Susceptible genes for hypertension.
(1) Angiotensin converting enzyme (ACE)
(2) α-adducin (ADD1)
(3) Adiponectin (ADIPOQ)
(4, 5, 6) β1/β2/β3 adrenergic receptor (ADRB1/2/3)
(7) Angiotensinogen (AGT)
(8) Angiotensin II type1 receptor (AGTR1)
(9) Aldehyde dehydrogenase 2 (ALDH2)
(10) Rho-GTPase activating protein-8 (ARHGAP8)
(11) Bradykinin receptor β2 (BDKRB2)
(12) Fas ligand (FASL)
(13) G protein-coupled receptor kinase 4 (GRK4)
(14) Human 8-hydroxyguanine DNA-glycosylase (hOGG1)
(15) Methylenetetrahydrofolate reductase (MTHFR)
(16) Regulator of G protein signaling-2 (RGS2)
(17) Solute carrier family 12 member 3 (SLC12A3)
(18) Transforming growth factor-β (TGFB1)
(rs11643718), and TGFB1 Leu10Pro (rs1982073)) for which
positive associations with hypertension were previously
reported were successfully determined using TaqMan PCR
method (Applied Biosystems Inc., Foster City, CA, USA).
According to quantitative RT-PCR analysis using cDNA
extracted from peripheral blood, 11 genes were expressed in
peripheral blood: ACE, ADD1, ADRB1, ADRB2, ARHGAP8,
FASL, GRK4, MTHFR, RGS2, SLC12A3, and TGFB1. RNA
samples were extracted from the peripheral blood of the
subjects, and cDNA was made from RNA using reverse
transcriptase. Quantitative real-time PCR (RT-PCR) for all
the genes was performed using TaqMan PCR method to
determine their expression levels.
2.3. Statistical Analysis. The associations between polymor-
phisms and clinical variables were analyzed using one-
way analysis of variance (ANOVA). The diﬀerence in each
genotype or allele distribution was examined by χ2 analysis.
Odd ratios were calculated as an index of the association of
each genotype with the prevalence of hypertension. To assess
the contribution of confounding factors, we performed
multiple logistic regression analysis using the computer
software application, JMP 7.0 (SAS Institute Inc., Cary, NC,
U.S.A.).WefocusedontestingforSNPmedicationandgene-
expression medication interactions (i.e., whether the eﬀects
of SNPs on systolic BP or diastolic BP diﬀered between
hypertensives on azelnidipine and temocapril). Multivariate
analysisofvariance(MANOVA)wasperformedtodetermine
whether BP change showed a signiﬁcant interaction of
each antihypertensive medication with the genotypes of the
susceptible genes.
3. Results
3.1.BaselineCharacteristicsofSubjectsTreatedwithAzelnidip-
ine and Temocapril. Baseline characteristics of the subjects
treated with azelnidipine and temocapril are shown inInternational Journal of Hypertension 3
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Addition of other medication
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Azelnidipine 16 mg
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Addition of other medications
Figure 1: Study protocol; wk: week.
Table 2. There was no diﬀerence in sex, age, body mass index
(BMI), aﬀected period of hypertension, systolic BP, triglyc-
eride level, LDL cholesterol level, and serum creatinine level
between the azelnidipine and temocapril groups; however,
fasting glucose level was higher in the azelnidipine group
than in the temocapril group at the baseline.
3.2. BP Reduction with Azelnidipine and Temocapril. In the
current study, the same level of BP reduction was observed
in both the azelnidipine and temocapril groups, and both
groups achieved a mean BP of less than 130/80mmHg at 52
weeks. There was no diﬀerence in the dose of each treatment
at 52 weeks (group started with azelnidipine: BP at 52 weeks
121.9 ± 11.4/74.7 ± 7.1mmHg, ﬁnal dose of azelnidipine
15.0 ± 2.7mg, ﬁnal dose of temocapril 3.8 ± 0.6mg;group
started with temocapril: BP at 52 weeks 125.6 ± 10.3/74.7 ±
6.1mmHg,ﬁnaldoseofazelnidipine14.9±2.8mg,ﬁnaldose
of temocapril 3.7 ±0.7mg, Figure 2).
3.3. Susceptible Gene Polymorphisms for Hypertension. The
genotypesof22polymorphismsofthe18genesweresuccess-
fully determined at each time point (0, 8, 16, and 52 weeks).
Only the Ile164Thr polymorphism of the adiponectin gene
has no mutant genotype, and the other genotype frequencies
were not signiﬁcantly diﬀerent from the values of Hardy-
Weinberg’s expectation (Figure 3).
According to the analysis of the association between BP,
changes of BP, and all genotypes at each time point (0, 8,
16, and 52 weeks), only the A-638G polymorphism of the
regulator of G protein signaling-2 gene (RGS2) showed a
signiﬁcant association with changes in BP (ΔB P :B Pa t8
weeks—BP at 0 week). As shown in Figure 3, there was a
signiﬁcant relationship between the A-638G polymorphism
of the RGS2 gene and the changes in BP between 0 and 8
weeksinsubjectswithazelnidipine(ΔsystolicBP:AA−28.0±
10.1mmHg,AG−15.5±12.6mmHg,GG+7.0±12.2mmHg,
P = .0013; Δdiastolic BP: AA − 17.2 ± 9.8mmHg, AG −
8.1 ± 9.0mmHg, GG − 4.0 ± 11.0mmHg, P = .067), but
not in subjects with temocapril (Δsystolic BP: AA − 5.3 ±
11.8mmHg, AG−8.4±13.0mmHg, GG−9.9±10.0mmHg,
P = .81; Δdiastolic BP: AA − 0.5 ± 7.2mmHg, AG − 4.4 ±
3.5mmHg, GG − 10.0 ± 4.5mmHg, P = .34). At 8 weeks,
changes in BP showed a signiﬁcant interaction between
A-638G and treatment with azelnidipine and temocapril
(Δsystolic BP, Δdiastolic BP: P = .0014, P = .036, resp., by
MANOVA, after adjustment for age, sex, and BMI) (Table 3).
T h e r ew a sn og e n ew h o s ee x p r e s s i o nw a sa s s o c i a t e d
with BP phenotypes or the polymorphisms of each gene
through analysis of gene expression in peripheral blood. In
terms of the RGS2 gene, the A-638G polymorphism was not
related to the change of RGS2 expression between 0 and 8
weeks either in subjects with azelnidipine (ΔRGS2/18sRNA
with azelnidipine: AA − 1.06 ± 2.1, AG +0 .31 ± 0.85,
GG +0 .57 ± 0.44, P = .13, Figure 4)o ri ns u b j e c t sw i t h
temocapril(ΔRGS2/18sRNAwithtemocapril:AA+0.75±1.3,
AG −0.10 ±0.62,GG+0 .38 ±0.44, P = .24, Figure 4).
4. Discussion
This study demonstrated the importance of pharmacoge-
netic research. Previously, Lynch et al. reported that the
NPPA T2238C variant was associated with modiﬁcation
of antihypertensive medication eﬀects on cardiovascular
disease and BP, and TT allele carriers had more favorable
outcomes when randomized to receive a CCB (amlodipine)
[17]. Beitelshees et al. also demonstrated that the KCNMB1
genotype inﬂuenced responsiveness to verapamil SR and risk
ofadversecardiovascularoutcomes[18].Thesereportscould
support the possibility of the existence of genes inﬂuencing
drug eﬃcacy.
Signaling by G-protein-coupled neurotransmitter recep-
tors in the autonomic nervous system and vasoregula-
tory factor receptors in the periphery governs both blood
pressure, by controlling the constriction and dilatation of
resistance arterioles, and electrolyte and ﬂuid balance by
the kidney [19, 20]. The recently identiﬁed regulator of G-
protein signaling (RGS) proteins is important in regulating4 International Journal of Hypertension
Table 2: Baseline characteristics of subjects treated with azelnidipine and temocapril.
Azelnidipine Temocapril P value
n 23 21
Male/Female (n), (%) 18/5 (78/22) 15/6 (71/29) .60
Age (years) 60.8 ±7.96 1 .0 ±8.5. 9 6
BMI (Kg/m2)2 5 .6 ±4.32 5 .8 ±3.3. 8 5
Period of HT (yr) 5.3 ±5.79 .0 ±12.8. 2 1
Systolic BP (mmHg) 155.1 ±11.1 157.2 ±10.2. 5 2
Diastolic BP (mmHg) 97.8 ±5.79 5 .2 ±5.4. 1 4
Fasting BG (mg/dL) 147.4 ±27.5 132.3 ±19.4. 0 4
TG (mg/dL) 127.3 ±54.7 129.1 ±61.3. 9 2
LDL-cholesterol (mg/dL) 136.1 ±39.5 137.0 ±39.0. 9 4
Serum Cr (mg/dL) 0.75 ±0.12 0.77 ±0.15 .58
HT: hypertension, BP: blood pressure, BG: blood glucose, TG: triglyceride, LDL: low density lipoprotein, and Cr: creatinine (mean±SD).
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Figure 2: BP reduction with azelnidipine and temocapril; BP: blood pressure, SBP: systolic BP, and DBP: diastolic BP.
signaling cascades initiated by G-protein-coupled receptors
(GPCRs) activation [21]. RGS proteins facilitate the intrinsic
inactivating guanosine triphosphatase reaction of G-protein
a-subunits , and thereby serve as eﬀector channel blockers.
RGS2 is unique among the RGS proteins in its apparent
selectivity towards Gpa, which mediates the action of mouse
physiological vasoconstrictors, including norepinephrine,
angiotensin II, endothelin-1, and thrombin. RGS2 can also
attenuate Gi- and Gs-mediated pathways [22, 23], which can
alsoaﬀectbloodpressureviaotherphysiologicallyimportant
agonists such as serotonin, dopamine, and bradykinin. It was
recently reported that mice lacking RGS2 exhibit a strong
hypertensive phenotype (increase in SBP of 50mmHg)
and resistance vasculature [24, 25]. Both heterozygous and
homozygous RGS2-null mice exhibited a similar level of
marked hypertension, suggesting that a naturally occurring
mutation that aﬀects the level of RGS2 protein may have
a signiﬁcant impact on blood pressure regulation. Recently
there have been two reports that genetic changes in RGS2
are associated with a hypertensive phenotype [26, 27]. A-
638G, T1026A, and 1891-1892 del TC polymorphisms were
extracted on the condition the allele frequencies of these
polymorphisms were >0.1, and the T1026A and 1891-1892
del TC polymorphisms of this gene were associated with
hypertension in women. These ﬁndings suggest that some
functional variants of the RGS2 gene might be involved in
regulating blood pressure in humans.
This ATTEST gene study revealed that one possible
gene related to the eﬀect of antihypertensive agents. In the
current study, the A-638G polymorphism of the RGS2 gene
was a predictive factor for therapeutic performance of a
CCB, azelnidipine. Other classical candidate genes including
genes associated with the renin-angiotensin system, sodium
handling, vasodilatation and vasoconstriction, and the sym-
pathetic nervous system did not show signiﬁcant associa-
tion between their polymorphisms and the eﬀect of a Ca
channel blocker or ACE inhibitor. In addition, there was no
signiﬁcant relationship between RGS2 polymorphisms andInternational Journal of Hypertension 5
Table 3: Genotype frequencies of 22 SNPs.
SNP Name Major Homo (n)H e t e r o ( n) Minor Homo (n)
Hardy-Weinberg
Expectation (o
value)
ACE Ins/Del (I/D) II 15 ID 23 DD 6 0.54
ADD1 Gly460Trp (G/T) GG 10 GT 24 TT 10 0.55
ADIPOQ Ile164Thr (T/C) TT 44 TC 0 CC 0 -
ADRB1 Ser49Gly (G/A) GG 1 GA 6 AA 37 0.24
ADRB1 Arg389Gly (G/C) GG 3 GC 14 CC 27 0.53
ADRB2 Gly16Arg (A/G) AA 14 AG 18 GG 12 0.23
ADRB2 Glu27Gln (C/G) CC 41 CG 3 GG 0 0.81
ADRB3 Trp64Arg (T/C) TT 29 TC 13 CC 2 0.73
AGT Met235Trp (T/C) TT 31 TC 12 CC 1 0.90
AGTR1 A1166C (A/C) AA 36 AC 7 CC 1 0.38
ALDH2 Glu487Lys (G/A) GG 29 GA 13 AA 2 0.73
ARHGAP8 Arg338Gly (C/G) CC 9 CG 20 GG 15 0.63
BDKRB2 T-58C (T/C) TT 7 TC 23 CC 14 0.63
FASL G-670A (G/A) GG 16 GA 17 AA 11 0.15
GRK4 Ala486Val (C/T) CC 12 CT 20 TT 12 0.55
GRK4 Arg65Leu (G/T) GG 33 GT 9 TT 2 0.21
hOGG1 Ser326Cys (G/C) GG 7 GC 24 CC 13 0.46
MTHFR C677T (C/T) CC 16 CT 24 TT 4 0.24
RGS2 A to G in promoter (A/G) AA 9 AG 22 GG 13 0.96
RGS2 A-638G (A/G) AA 9 AG 23 GG 12 0.74
SLC12A3 Arg904Gln (G/A) GG 39 GA 5 AA 0 0.69
TGFB1 Leu10Pro (T/C) TT 12 TC 24 CC 8 0.51
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Figure 3: Relationship between A-638G polymorphism of RGS2 gene and BP change.6 International Journal of Hypertension
RGS2 expression
AA AG GG
−3
−2
−1
0
1
2
3
Azelnidipine (mean±SD)
Temocapril (mean±SD)
Δ
R
G
S
2
/
1
8
s
R
N
A
A-638G/RGS2
Figure 4: Relationship between A-638G polymorphism of RGS2
gene and RGS2 gene expression in peripheral blood.
BP-related phenotypes in this study, unlike previous reports.
It has not yet been reported that the promoter variant
A-638G of the RGS2 gene may change RGS2 function;
however, this polymorphism has the possibility to change
RGS2 protein production because this polymorphism is in
the promoter region. There has been no evidence supporting
theidea that RGS2 couldbe involved in theeﬀectof CCBs. In
several previous reports, genes without a drug-metabolizing
eﬀect, such as ACE [3]o rA G T R 1[ 4], showed a signiﬁcant
association between their polymorphisms and response to
antihypertensive medication; however, the mechanisms have
not been clariﬁed in any of these reports. In terms of the
present study, RGS2 is suggested to function as a switch
to turn on or oﬀ the G protein-associated pathway, and
RGS2 can regulate blood pressure through smooth muscle
cells. From this viewpoint, RGS2 might have the possibility
of changing the eﬀect of CCBs, because those mainly act
through SMC; however, the detailed mechanism merits
further investigation in the future.
Peripheral blood mainly contains white blood cells, red
blood cells, platelets, and other circulating hormones, so the
distribution of genes expressed in peripheral blood has to be
investigatedtoclarifythesigniﬁcanceofdiseasesusceptibility
gene expression in peripheral blood. In the present study,
11 genes were expressed in peripheral blood. There was no
signiﬁcant relationship between gene expression including
the RGS2 gene and the eﬀect of antihypertensives and phe-
notypes.Fromthisviewpoint,RGS2expressioninperipheral
blood does not seem to do anything and might not be a
marker for BP regulation. However, further study is needed
on its clinical application as a marker of drug eﬃcacy.
As the limitation of this study, we could not exclude
the possibility of the false positive association (type I error)
due to the use of small number of subjects. However, this
study was carried out under the strict protocol of a clinical
trial so that the reliability of the results obtained seems to
be high. To conﬁrm the eﬀect of RGS2 gene in the tailored
medicine of hypertension, further study using another panel
of hypertensive subjects should be required.
In conclusion, the A-638G polymorphism of the RGS2
gene could be a predictive factor for therapeutic eﬀectiveness
of CCBs such as azelnidipine. Further research is needed
to determine the optimal approach for personalizing anti-
hypertensive medication treatment regimens according to
genotype information and for achieving the best blood
pressure control.
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